Press Releases

March 1, 2018
Protagonist to Announce Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018; Year-End Update Call to Follow Read More
January 31, 2018
Protagonist Therapeutics to Participate in the Leerink Partners 7th Annual Global Healthcare Conference Read More
January 4, 2018
Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300 Read More
December 14, 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors Read More
December 14, 2017
Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 Read More
December 4, 2017
Protagonist Therapeutics to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference Read More
November 9, 2017
Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200 Read More
November 6, 2017
Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update Read More
November 1, 2017
Protagonist Therapeutics to Present at the Stifel 2017 Healthcare Conference Read More
October 11, 2017
Protagonist Therapeutics Prices Public Offering of Common Stock Read More
October 11, 2017
Protagonist Therapeutics Announces Proposed Public Offering of Common Stock Read More
September 20, 2017
Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 Read More
September 14, 2017
/C O R R E C T I O N -- Protagonist Therapeutics, Inc./ Read More
September 11, 2017
Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Read More
August 24, 2017
Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment Read More
August 8, 2017
Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights Read More
June 8, 2017
Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors Read More
May 30, 2017
Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease Read More
May 25, 2017
Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 Read More
May 24, 2017
Protagonist Therapeutics Receives $1.34 Million SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist Activity Read More